PCM
ARCT icon

Portolan Capital Management’s Arcturus Therapeutics ARCT Stock Holding History

Portolan Capital Management’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-129,144
Closed -$3M – 135
2024
Q3 		$3M Sell
129,144
-355,763
-73% -$7.61M 0.22% 110
2024
Q2 		$11.8M Buy
484,907
+240,248
+98% +$7.29M 0.97% 38
2024
Q1 		$8.26M Buy
244,659
+98,805
+68% +$3.5M 0.63% 59
2023
Q4 		$4.6M Sell
145,854
-130,651
-47% -$3.11M 0.4% 81
2023
Q3 		$7.06M Buy
+276,505
New +$8.52M 0.66% 48

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Portolan Capital Management's ARCT Position: Q4 2024 in Review

Portolan Capital Management sold out of Arcturus Therapeutics (ARCT) in Q4 2024, closing a stake of 129,144 shares — an estimated $3M sold.

Portolan Capital Management first reported a position in ARCT in Q3 2023 and held it in 5 quarters. The position peaked at $11.8M in Q2 2024. 147 funds tracked by Wall St. Rank hold ARCT as of Q4 2024.

  • Portolan Capital Management reported no remaining Arcturus Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Portolan Capital Management sold 129,144 Arcturus Therapeutics shares in Q4 2024, an estimated $3M.
  • Portolan Capital Management first reported a position in Arcturus Therapeutics in Q3 2023 and held it in 5 quarters.
  • Portolan Capital Management's Arcturus Therapeutics position peaked at $11.8M in Q2 2024.
  • 147 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q4 2024.

Based on Portolan Capital Management's 13F filing for Q4 2024, filed 13 Feb 2025.